TG TherapeuticsFRA:NKB2 +1.59%81 PE Ratio (TTM) is 20.89 as of Jul. 12, 2026, which is 71% below its 10-year median of 72.19. GuruFocus rates FRA:NKB2 with a GF Score™ of 81/100 and a GF Value™ of €48.73 (Fairly Valued). The stock has 8 warning signs investors should review. Among 271 Biotechnology companies, TG Therapeutics ranks better than 60.15% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-12), TG Therapeutics's share price is
€51.00.
TG Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €2.44. Therefore, TG Therapeutics's PE Ratio (TTM) for today is 20.89.
The historical rank and industry rank for TG Therapeutics's PE Ratio (TTM) or its related term are showing as below:
FRA:NKB2'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 10.09 Med: 72.19 Max: 1965
Current: 19.97
During the past 13 years, the highest PE Ratio (TTM) of TG Therapeutics was 1965.00. The lowest was 10.09. And the median was 72.19.
FRA:NKB2's PE Ratio (TTM) is ranked better than 60.15% of 271
companies
in the Biotechnology industry
Industry Median: 27.41
vs FRA:NKB2: 19.97
During the past 13 years, TG Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 86.20% per year. The lowest was -76.50% per year. And the median was 16.75% per year.
TG Therapeutics's EPS (Basic) for the
three
months ended in Mar. 2026 was €0.12.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €2.72.
TG Therapeutics (FRA:NKB2) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
TG Therapeutics PE Ratio (TTM) Related Terms
TG Therapeutics PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for TG Therapeutics's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NKB2 vs HALO, KYMR, PCVX: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, TG Therapeutics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
TG Therapeutics's Share Price of today is €51.00.
TG Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.44.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
TG Therapeutics (FRA:NKB2) has a PE Ratio (TTM) of 20.89 as of Jul. 12, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on TG Therapeutics and its competitors. This is 71% below median its historical median of 72.19. Over the past decade, TG Therapeutics' PE Ratio (TTM) has ranged from 10.09 to 1,965.00. According to the industry distribution chart, TG Therapeutics ranks #108 out of 271 companies in the Biotechnology industry, placing it in the top 39.9%.
Is TG Therapeutics' PE Ratio (TTM) too high?
TG Therapeutics' current PE Ratio (TTM) of 20.89 is 71% below median its 10-year median of 72.19. Over the past 10 years, this metric has ranged from a low of 10.09 to a high of 1,965.00. The Biotechnology industry median PE Ratio (TTM) is 27.41. TG Therapeutics' value of 20.89 is 23.8% below this industry median. Based on the distribution chart, TG Therapeutics ranks #108 out of 271 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TG Therapeutics has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' PE Ratio (TTM) compare to HALO and KYMR?
According to the Biotechnology industry distribution chart, TG Therapeutics ranks #108 out of 271 companies for PE Ratio (TTM). This puts TG Therapeutics in the upper half of its industry. The industry median PE Ratio (TTM) is 27.41. TG Therapeutics' value of 20.89 is 23.8% below this benchmark. Historically, TG Therapeutics' own PE Ratio (TTM) has ranged from 10.09 to 1,965.00 over the past decade. While the company's 10-year median is 72.19 vs. the industry median of 27.41, TG Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 27.41, based on 271 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TG Therapeutics's current PE Ratio (TTM) of 20.89 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on TG Therapeutics and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 27.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TG Therapeutics's current PE Ratio (TTM) is 20.89, which is 71% below median its own 10-year median of 72.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The stock's GF Value™ is €48.73, compared to a current price of €51.00 — trading 4.7% above its estimated fair value. The current PE Ratio (TTM) is 20.89, which is 71% below median its 10-year median of 72.19 and 23.8% below the Biotechnology industry median of 27.41. TG Therapeutics' overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current PE Ratio (TTM) is 20.89 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?
Based on GuruFocus' analysis, TG Therapeutics stock appears to be overvalued.
The current stock price of €51.00 is trading 4.7% above its estimated GF Value™ of €48.73.
GuruFocus considers TG Therapeutics to be Fairly Valued.
Key valuation signals for FRA:NKB2:
PE Ratio (TTM): 20.89 (71% below median its 10-year median of 72.19)
GF Value™: €48.73 vs. price of €51.00 (4.7% above fair value)
Industry Position: 23.8% below the Biotechnology median (#108 of 271)
No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
81GF Score
Get the complete analysis for FRA:NKB2
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NKB2 has been successfully added to your 
